Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.
Sihuan Pharmaceutical announced that Xuanzhu Biopharm has completed enrollment of all 500 subjects in a phase III clinical trial in China for Anaprazole Sodium Enteric-coated Tablets, branded An Jiu Wei, in adults with reflux esophagitis. The pivotal, multicentre, randomized and double-blind study compares the drug’s efficacy and safety against an active control, focusing on endoscopic healing rates and improvements in key symptoms such as heartburn and regurgitation.
Anaprazole Sodium is already approved in China for duodenal ulcer and is positioned as a next-generation proton pump inhibitor designed to minimize CYP2C19-related variability and drug-drug interactions, particularly benefiting patients on multiple medications or with renal impairment. Successful phase III results and a future label expansion into reflux esophagitis would deepen Sihuan’s gastrointestinal portfolio, enhance Xuanzhu Biopharm’s innovative drug credentials and potentially strengthen the group’s competitive standing in China’s large market for acid-related gastrointestinal disorders.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group is a China-focused international medical aesthetics and pharmaceutical company, founded in 2001 and listed in Hong Kong since 2010. Through its non-wholly-owned subsidiary Xuanzhu Biopharm, it develops innovative class 1 drugs targeting major diseases in digestion, oncology and liver-related conditions, supported by small and large molecule R&D platforms and an extensive domestic sales network.
Xuanzhu Biopharm, also listed in Hong Kong, concentrates on R&D, production and commercialization of drugs with core proprietary intellectual property, including small molecules, biologics and antibody-drug conjugates. The group aims to strengthen its positioning as a leading Chinese biopharmaceutical and medical aesthetics player via a dual-engine strategy combining innovation-driven pipelines with cost-efficient, full-dosage production capabilities.
YTD Price Performance: 12.20%
Average Trading Volume: 32,267,503
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.88B
For a thorough assessment of 0460 stock, go to TipRanks’ Stock Analysis page.